Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients Mechelen, Belgium and Paris, France, 11 JUNE 2019, 07.00 CET - Servier and Galapagos NV (Euronext & NASDAQ: GLPG) completed recruitment for their ROCCELLA Phase 2 trial with GLPG1972/S201086, ahead of schedule. ROCCELLA is a multi-regional, randomized, double-blind,placebo-controlled, dose ranging trial evaluating the efficacy and safety of three different once-daily oral doses of GLPG1972/S201086 in patients with knee osteoarthritis (OA). ROCCELLA includes more than 850 patients in 12 countries in Europe, Asia, North and South America. Galapagos is...
|
